Artiva Biotherapeutics (ARTV) Accumulated Expenses (2023 - 2026)

Artiva Biotherapeutics (ARTV) has 4 years of Accumulated Expenses data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses fell 50.07% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 50.07% decrease from a year earlier, with the FY2025 full-year figure at $9.6 million, up 98.72% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $3.2 million, down from $9.6 million in the prior quarter.
• Over the last five years, Accumulated Expenses for ARTV reached as high as $9.6 million in Q4 2025 and fell as low as $3.2 million in Q1 2026.
• Historically, Accumulated Expenses has averaged $6.0 million across 4 years, with a median of $5.8 million in 2025.
• Across the five-year window, Accumulated Expenses jumped 98.72% in 2025 and plunged 50.07% in 2026, its largest moves.
• Year by year, Accumulated Expenses stood at $4.0 million in 2023, then grew by 19.37% to $4.8 million in 2024, then soared by 98.72% to $9.6 million in 2025, then sank by 66.84% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $3.2 million in Q1 2026, $9.6 million in Q4 2025, and $5.6 million in Q3 2025.